The titration score of ABO antibodies in mercapto-treated sera corresponds well with the severity of hemolytic disease of ABO incompatible infants. Adoptation of this “mercapto-test” as an ABO incompatibility test will make possible prediction of infant's hemolytic disease and facilitate preparation for treatment.
